Business overview
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
Latest developments
Current filings are unavailable from the source.
Latest results
No annual or quarterly results are available.
Key risks
Annual risk disclosures are unavailable.
Quarterly risk disclosures are unavailable.
Annual report details
An annual report is unavailable for this company.
Sources & About this page
Business overview: company description supplied by EFDP stock comparison metrics.
Open EFDP dashboard